| Previous Section | Index | Home Page |
27 Jan 2010 : Column 941W—continued
Blood: Donors
Mr. Hancock: To ask the Secretary of State for Health how many people have received blood components from 80 or more donors in each of the last five years. [313623]
Gillian Merron: This Information is not collected centrally.
Chronic Fatigue Syndrome
Mr. Drew: To ask the Secretary of State for Health what recent representations he has received on making myalgic encephalomyelitis a notifiable illness for the purposes of blood donation. [313595]
Ann Keen: The Department has received 31 representations on making myalgic encephalomyelitis a notifiable illness in the last six months. There have also been a number of representations on this subject received by the Chief Medical Officer.
Mr. Drew: To ask the Secretary of State for Health whether his Department plans to (a) commission and (b) evaluate research on the possible health effects of receiving blood donated by a person with myalgic encephalomyelitis. [313596]
Ann Keen: The Department has no current plans to directly commission research on this issue. However, the Medical research Council has designated myalgic encephalomyelitis/chronic fatigue syndrome a priority research area, and will fund proposals of sufficient quality. The UK Blood Services together with the Health Protection Agency are undertaking a study of the prevalence of a rodent virus recently linked to myalgic encephomyelitis, which will be used to inform a risk assessment.
Mr. Drew: To ask the Secretary of State for Health whether his Department plans to test patients for xenotropic murine leukaemia virus-related illnesses. [313607]
Ann Keen: There are currently no plans to test patients for xenotropic murine leukaemia virus-related virus.
CJD
Mr. Hancock: To ask the Secretary of State for Health how many potential vCJD treatments are being tested in the UK; and what stage each trial has reached. [313609]
Gillian Merron: There is no proven therapy for patients with variant Creutzfeldt-Jakob disease (vCJD), nor are there any clinical trials for vCJD treatments in progress in the United Kingdom.
Some current UK vCJD patients are being treated with Pentosan Polysulphate, which may extend life, on an individual basis.
The Department is currently providing funding for a six-year multi-million pound collaboration between the MRC Prion Unit and GlaxoSmithKline with the objective of developing an effective drug for human prion infection and disease. In addition the National Prion Monitoring Cohort study, also funded by the Department at the MRC Prion Unit, has as an objective to monitor use of anti-prion agents if and when used.
Mr. Hancock: To ask the Secretary of State for Health how many cases of vCJD have been diagnosed in each of the last 10 years (a) in total and (b) in each genotype. [313610]
Gillian Merron: The National Creutzfeldt-Jakob disease Surveillance Unit:
reports the number of cases diagnosed as:
| Diagnosis | |
All cases of variant Creutzfeldt-Jakob Disease (vCJD) where the genotype is known are MM at codon 129 of the PrP gene.
There has been one case of possible vCJD reported in a patient with MV genotype at codon 129 of the PrP gene. This patient did not fulfil the probable clinical case definition for vCJD as set by the World Health Organization, and is therefore not included in the figures for definite or probable vCJD.
Bob Russell: To ask the Secretary of State for Health how many people have contracted vCJD from contaminated blood via blood transfusion in each of the last five years; how many such people contracted vCJD from non-leucodepleted blood; and if he will make a statement. [314084]
Council for Healthcare Regulatory Excellence: Finance
Mr. Todd: To ask the Secretary of State for Health what assessment he has made of the reason for the cost of the finance function for (a) the Council for Healthcare Regulatory Excellence and (b) the NHS Litigation Authority referred to in the publication Benchmarking the Back Office: Central Government; and if he will make a statement. [312680]
Mr. Mike O'Brien: The costs of these functions are currently under review as part of the Operational Efficiency programme.
Departmental Disclosure of Information
David Davis:
To ask the Secretary of State for Health whether (a) agencies and (b) non-departmental public bodies for which his Department is responsible sell
information on a commercial basis to (i) companies or individuals in the private sector and (ii) other organisations. [313226]
Phil Hope: In common with executive agencies, and non-departmental public bodies (NDPBs) across central Government that have Crown status, the Department's agencies and NDPBs make most of their information available for free re-use under the PSI Click-Use Licence. Some information is contained in priced publications. Government trading funds, including the Medicines and Healthcare products Regulatory Agency for which Department's Ministers have responsibility, are able to charge for the services they provide in order to cover their costs. This includes charging for the provision of information to other public bodies, commercial organisations and individuals.
Departmental Pay
Norman Lamb: To ask the Secretary of State for Health what the total monetary value of Senior Civil Service (SCS) non-consolidated performance pay awards was in his Department in each of the last five years; how many and what proportion of SCS staff in each pay band received awards in each year; and how much in each award category was received by staff in each pay band each year. [300382]
Phil Hope: Non-consolidated performance payments to senior civil servants are made under the terms set out in the Government's response to the recommendations of the independent Senior Salaries Review Body. A close and effective link between pay and performance and increased use of variable pay is a key element of the reward arrangements for the senior civil service. The total spend on non-consolidated performance pay in each of the last five years was given in the written answer I gave the hon. Member for Twickenham (Dr. Cable) on 25 January 2010, Official Report, columns 544-546W.
The numbers and proportions of senior civil servants receiving non-consolidated performance pay in 2004-05, 2005-06 and 2006-07 is available only at disproportionate cost as the Department's human resources information system does not hold the information in a format which can easily be translated into performance groups. For the last two years, the numbers of senior civil servants in receipt of end year non-consolidated performance pay was:
| 2008-09 | ||||||||||||||||||||||
| Number and percentage of staff in performance related pay category | ||||||||||||||||||||||
| Grade | 1 | 2 | 3B | 3NB | 4 | |||||||||||||||||
| No. | % | No. | % | No. | % | No. | % | No. | % | Total no. | ||||||||||||
| Note: Groups 1, 2 and 3B received non-consolidated performance pay whereas groups 3NB and 4 did not. | ||||||||||||||||||||||
| 2007-08 | |||||||||
| Number and percentage of staff in performance related pay category | |||||||||
| Grade | 1 | 2 | 3B | 4 | |||||
| No. | % | No. | % | No. | % | No. | % | Total no. | |
| Note: Groups 1,2 and 3B received non-consolidated performance pay whereas group 4 did not. | |||||||||
| Next Section | Index | Home Page |